Reassessing the Safety and Efficacy of Very Low LDL Cholesterol
Though cholesterol-lowering guidance often touts the achievement of very low levels of low-density lipoprotein (LDL) cholesterol, emerging research demonstrates possible…
Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies
The 2025 National Lipid Association (NLA) Scientific Sessions highlighted a strategic shift toward early, aggressive cardiometabolic intervention, underscoring the vital…
Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC
Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy.
Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease
FDA approves a new dosing schedule for donanemab, enhancing safety and efficacy in treating early symptomatic Alzheimer disease.
Community Pneumococcal Vaccination Support Program for Older Adults Reduces Pneumonia-Related Mortality
In a community of older adults, initiating a pneumococcal vaccination support program reduced annual pneumonia-related mortality by 25%, demonstrating broad…
McKesson ideaShare 2025 Set to Empower Pharmacy Professionals in Nashville
Packed with CE sessions, interactive learning, expert insights, and a vibrant expo floor, McKesson ideaShare 2025 aims to equip independent…
IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma
New data reveals isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.
Evolving Strategies for RSV: Understanding Respiratory and Cardiovascular Impacts, Prevention, and Future Directions
Understanding RSV’s impact on both respiratory and cardiovascular health underscores the importance of holistic management, prevention through vaccination, and continued…
Humana’s CenterWell is acquiring The Villages Health in Florida
CenterWell, owned by Humana, is buying The Villages Health in Orlando, Florida, according to a notice from the healthcare provider…
Radiation or Immune-Modulating Drugs Could Mitigate Resistance to CDK4/6 Inhibitors in Breast Cancer
Research reveals that combining radiotherapy or immune-modulating drugs with CDK4/6 inhibitors enhances treatment efficacy in HR+/HER2– breast cancer.